This is a Phase IV, multicenter, open-label, single-arm study of somatropin (rDNA origin)
(Nutropin AQ v1.1) in pre-pubertal children with growth hormone deficiency (GHD) naive to
prior recombinant human growth hormone (rhGH) treatment. The study is designed to
characterize the immunogenicity profile of Nutropin AQ v1.1 when administered as a daily
subcutaneous (SC) injection for 12 months. The clinical impact of immunogenicity will also
be assessed. The target sample size is 8...

The purpose of the study is to evaluate the safety and effectiveness of ALTU-238 in the
treatment of children with growth hormone deficiency who have not yet reached puberty who
lack the normal ability to make growth hormone themselves. This study will also test if
ALTU-238 works as a weekly treatment.

To evaluate the safety and efficacy of PEG Somatropin Injection (Jintrolong®) in the
treatment of short stature due to endogenous growth hormone deficiency (GHD) in the broad of
population of children.

To evaluate the safety and efficacy of PEG Somatropin Injection in the treatment of children
with growth hormone deficiency, as well as to study the feasibility of extending the dosing
intervals (once per two weeks) of PEG Somatropin Injection.

Annualised height velocity after 12/24 months treatment and HV SDS height velocity after
12/24 months treatment expressed as number of standard deviations difference from the mean
population height velocity for the appropriate gender and chronological age.

1. To further evaluate the safety and efficacy of PEG-Somatropin in the treatment of
children with growth hormone deficiency for a relatively long period
2. To explore the factors influencing the efficacy of PEG-Somatropin and to establish the
height prediction model based on Chinese children with short stature, and to provide the
basis and guidance for standard and reasonable long-term clinical application of
PEG-Somatropin.

The investigators hypothesize that the anabolic effects of Genotropin (somatropin) will
improve the height and weight of children with inflammatory based chronic illness who have
failed to grow despite receiving adequate nutrition. The investigators will test the
hypothesis by treating 32 chronically ill children (16 JRA and 16 Crohn's) with growth
hormone (GH) for 12 months and comparing them to baseline.

IGF-1 (insulin-like growth factor-1) is a hormone that is normally produced in the body in
response to another hormone called growth hormone. Growth Hormone is produced by a small
gland at the base of the brain (the pituitary). Together IGF-1 and GH are large contributors
to growth during infancy, childhood, and adolescence.
Children with IGF Deficiency are short and have an imbalance in the levels of growth hormone
and IGF-1 that their body produces. Their growth hormone lev...

Multi-center, randomized, controlled, open-label, phase III study comparing the effects of
two different dosages of somatropin treatment (in-label or doubled) after 12 and 24 months
of treatment, on height velocity in early pubertal children with growth hormone deficiency
(GHD). The study will be conducted in Italy. Approximately 26 subjects will participate in
this study, distributed as 13 in the in-label dosage group (group A) and 13 in the doubled
dosage group (group B).

This clinical trial will compare the mean first year height velocity of somatropin-treated
prepubertal patients with SHOX deficiency with the height velocity of a control group of
untreated prepubertal patients with SHOX deficiency. Both groups will be compared to a
somatropin-treated group of girls with Turner syndrome. After the second year patients in
the control group have the option to receive treatment as well. All patients will optionally
be treated until they achieved a...

This study aims to examine the safety, tolerability and pharmacokinetics of transdermal
delivery of human Growth Hormone (hGH or somatropin) using the ViaDerm device in adult
patients with Growth Hormone Deficiency Syndrome.

This trial is conducted in the United States of America (USA). The purpose of the trial is
to compare the effect of Norditropin® using different dosing regimens in children suspected
of growth hormone deficiency.

An international study in which patients with GHD were randomized to receive somatropin at a
dose of either 3 microg/kg/day or 6 microg/kg/day for the first three months. The dose was
then doubled (6 microg/kg/day, LD or 12 microg/kg/day, CD) for the next three-months.

This study is conducted globally. The purpose is to demonstrate the efficacy of once weekly
dosing of NNC0195-0092 compared to placebo and once-daily dosing of somatropin (human growth
hormone, hGH) after 35 weeks of treatment in adults with growth hormone deficiency.

This trial is conducted in Japan. To investigate the long-term efficacy as assessed by
change in fat mass and safety after 48 weeks of treatment of Growth Hormone in adults with
Growth Hormone Deficiency, comparing two different treatment regiments.

This trial is conducted in Japan. The aim of this trial is to demonstrate superiority of the
effect of NN-220 compared with that of placebo as assessed by the change in percent in
truncal fat (kg) from baseline to 24 weeks' treatment (end of treatment) in patients with
Growth Hormone Deficiency in Adults (GHDA).

This study is conducted in Japan. The aim of this observational study is to collect
information about the safety and efficacy of Norditropin® long-term treatment of growth
hormone deficiency in adults.

The purpose of the study is to evaluate the effects of growth hormone replacement on women
with growth hormone deficiency. Growth hormone deficiency means the body no longer produces
growth hormone due to a tumor or some kind of disease of the brain in an area called the
pituitary/hypothalamic region. This is the area of the brain where growth hormone is
normally produced. We, the researchers at Massachusetts General Hospital, will establish
the effects of growth hormone rep...